Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Oliver Hendricks

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases

English

Efficacy and Safety of Cannabidiol Followed by an Open Label Add-On of Tetrahydrocannabinol for the Treatment of Chronic Pain in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis: Protocol for a Multicentre, Randomised, Placebo-Controlled Study

BMJ Open

Medicine

2019

English

Related publications

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy

2019

English

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

English

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

Biologics in Therapy

2013

English

Prm42 - Cost Model of Switching From Enbrel to Etanercept Biosimilars, for Non Medical Reasons, in Rheumatoid Arthritis Patients in Spain

English

A Real Concern or Just a Hype? – Evidence on Negative Clinical Consequences of Switching From Originator to Biosimilar Based on a Systematic Literature Review

English

Does a Mandatory Non-Medical Switch From Originator to Biosimilar Infliximab Lead to Increased Use of Outpatient Healthcare Resources? A Register-Based Study in Patients With Inflammatory Arthritis

English

SAT0161 Preliminary Real World Data on Switching Patterns Between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry

2017

English

Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

English

Position on Non-Medical Switching for Diabetes Patients

Journal of Diabetes, Metabolic Disorders & Control

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Oliver Hendricks

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Efficacy and Safety of Cannabidiol Followed by an Open Label Add-On of Tetrahydrocannabinol for the Treatment of Chronic Pain in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis: Protocol for a Multicentre, Randomised, Placebo-Controlled Study

Related publications

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

Prm42 - Cost Model of Switching From Enbrel to Etanercept Biosimilars, for Non Medical Reasons, in Rheumatoid Arthritis Patients in Spain

A Real Concern or Just a Hype? – Evidence on Negative Clinical Consequences of Switching From Originator to Biosimilar Based on a Systematic Literature Review

Does a Mandatory Non-Medical Switch From Originator to Biosimilar Infliximab Lead to Increased Use of Outpatient Healthcare Resources? A Register-Based Study in Patients With Inflammatory Arthritis

SAT0161 Preliminary Real World Data on Switching Patterns Between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry

Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

Position on Non-Medical Switching for Diabetes Patients